These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19707273)

  • 1. The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability.
    Beatty MN; Blumenthal PD
    Ther Clin Risk Manag; 2009 Jun; 5(3):561-74. PubMed ID: 19707273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
    Varma R; Sinha D; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes of Israeli gynecologists towards the levonorgestrel-releasing intrauterine system: a questionnaire survey.
    Ben-Haroush A; Oron G; Yogev Y; Yeshaya A; Kaplan B
    Eur J Contracept Reprod Health Care; 2004 Mar; 9(1):29-33. PubMed ID: 15352692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial.
    Gupta JK; Daniels JP; Middleton LJ; Pattison HM; Prileszky G; Roberts TE; Sanghera S; Barton P; Gray R; Kai J;
    Health Technol Assess; 2015 Oct; 19(88):i-xxv, 1-118. PubMed ID: 26507206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
    Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
    J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system.
    Fong YF; Singh K
    Contraception; 1999 Sep; 60(3):173-5. PubMed ID: 10640162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
    Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
    Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.
    Bednarek PH; Jensen JT
    Int J Womens Health; 2010 Aug; 1():45-58. PubMed ID: 21072274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
    Depypere H; Inki P
    Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term use of the levonorgestrel-releasing intrauterine system.
    Inki P
    Contraception; 2007 Jun; 75(6 Suppl):S161-6. PubMed ID: 17531611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
    Wildemeersch D
    Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the levonorgestrel intrauterine system in effective contraception.
    Attia AM; Ibrahim MM; Abou-Setta AM
    Patient Prefer Adherence; 2013; 7():777-85. PubMed ID: 23990713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
    Nelson AL
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.